CANOMICS

Multicentre discovery of breast cancer biomarkers

Coordinatore	UNIVERSITY OF SOUTHAMPTON    more  Organization address address: Highfield city: SOUTHAMPTON postcode: SO17 1BJ contact info Titolo: Dr. Nome: Sue Cognome: Edwards Email: send email Telefono: +44 2380 595000 Fax: +44 2380 592195
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	86˙400 €
EC contributo	86˙400 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-IRSES
Funding Scheme	MC-IRSES
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-08-01   -   2012-07-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF SOUTHAMPTON  Organization address address: Highfield city: SOUTHAMPTON postcode: SO17 1BJ contact info Titolo: Dr. Nome: Sue Cognome: Edwards Email: send email Telefono: +44 2380 595000 Fax: +44 2380 592195	UK (SOUTHAMPTON)	coordinator	32˙400.00
2	"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"  Organization address address: Soranou Efesiou 4 city: ATHENS postcode: 11527 contact info Titolo: Dr. Nome: Spiros D. Cognome: Garbis Email: send email Telefono: 302107000000 Fax: 302107000000	EL (ATHENS)	participant	28˙800.00
3	ST GEORGE'S HOSPITAL MEDICAL SCHOOL  Organization address address: Cranmer Terrace city: LONDON postcode: SW17 0RE contact info Titolo: Dr. Nome: Paul Cognome: Craven Email: send email Telefono: +44 20 8725 5012 Fax: +44 20 8725 0794	UK (LONDON)	participant	25˙200.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Breast cancer is the most common cause of death from cancer among European women, and over half of the worldwide breast cancer related mortalities occur in the developing world. Despite improvements in surgical techniques and chemoradiotherapy, the ability to cure patients with breast cancer remains limited and five year survival for patients with advanced disease is dismal. Expression profiling and biomarker discovery aims to provide means for tumour diagnosis, classification, and prediction of response to therapy and prognosis. This could potentially lead to the building of robust early detection modules, and personalised effective breast cancer therapies which would improve outcomes. The emerging field of proteomics targets the discovery of early stage biomarkers in biological tissue which could lead to new clinically valid biomarkers discovery.The goal of this application is to develop proteomic tests using different approaches for identification of breast cancer biomarkers which could ultimately form the basis of a screening and/or prognostication test. Using different biological samples and proteomic biomarkers’ discovery methods improves the prospects of classification and stratification of different biological groups. Early cancer detection, improved treatment selection and outcome are expected in return. This project is focused on early detection where comparative analysis of proteomes of normal individuals and patients with cancer, as well as different subgroups of patients, will be used to develop a “signature” of changes that are characteristic of breast cancer. Our study will be based on serum and breast tissue samples collected and analysed in 5 centres.'